SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is surging following a positive clinical update that highlights an annual recurrence rate of less than 1% in the open-label arm of its Phase III trial, fueling community optimism about the company's competitive position. Investors are actively discussing the trial's statistically significant results compared to industry standards, the high level of insider ownership, and growing anticipation for upcoming abstract presentations.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is trending as the community debates the geopolitical fallout of the ongoing conflict in the Middle East, specifically focusing on the closure of the Strait of Hormuz and the administration's call for international naval support. Investors are actively discussing the potential impact of these tensions on global energy prices, the effectiveness of proposed trade tariffs, and broader concerns regarding market stability as the administration navigates a complex coalition-building process.

Lemonade, Inc. is a holding company, which engages in the provision of insurance services. The firm's products include renters and homeowners insurance, and pet insurance. It offers insurance coverage under the homeowners multi-peril, inland marine, and general liability lines of business. The company was founded by Daniel Asher Schreiber and Shai Wininger on June 17, 2015 and is headquartered in New York, NY.

Lemonade Inc

Lemonade is seeing significant investor attention following a strategic partnership with Tesla that provides insurance discounts for FSD-enabled vehicles, fueling community speculation about data-driven growth. While the stock has experienced notable volatility and high short interest, bulls are focused on the company's AI-native insurance platform and its potential to scale rapidly against traditional carriers.

What is DAG? In more traditional blockchains, the host provides the food/drinks (i.e resources) for this party. And when the guests arrive, the amount of resources can only accommodate so many people, the portions are small and then everything eventually runs out and the party ends. Think Constellation DAG like a potluck (a party where everyone brings food/drinks). With every added guest (node to the network), the more resources the party has to keep going. This is the nature of Constellation, a distributed system that scales horizontally.  Is Constellation a Blockchain? Not exactly. Although inspired by the principles of decentralization, many standard blockchains such as Bitcoin and Ethereum face scalability issues. This is why the next, generation of decentralized networks such as Hashgraph, IOTA, and Constellation have turned to DAG.  What is a Microservice? “Microservices” is an approach to application development in which a large application is built as a suite of modular services. Each module supports a specific business goal and uses a simple, well-defined interface to communicate with other sets of services. Uber, for example, is not a singular app purse. It is a unified app which means it is a single interface that brings together their driver app, their rider app, and their corporate team app.

Constellation

Constellation (DAG) is trending as investors focus on its potential as a specialized data-validation layer, particularly through its recent merger agreement with AI holding company AIAI and its history of contracts with U.S. government and defense agencies. The community is actively weighing the long-term utility of the Hypergraph architecture against the risks of a slow retail rollout, with many highlighting potential enterprise integration with major cloud providers as the primary catalyst for future growth.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate is seeing intense market activity as investors position themselves for a series of high-stakes catalysts, including an imminent U.S. patent approval and a PDUFA decision for its ADHD treatment in late May. The community is actively discussing the stock's low float and the potential for a significant run, drawing parallels to its previous price action and highlighting strong institutional interest.

Tencent Music Entertainment Group engages in the business of operating online music entertainment platforms to provide music streaming, online karaoke, and live streaming services. Its product brands include QQ Music, Kugou Music, Kuwo Music, and WeSing. The company was founded on June 6, 2012 and is headquartered in Shenzhen, China.

Tencent Music Entertainment Group - ADR

Tencent Music Entertainment Group

Tencent Music Entertainment Group (TME) is seeing increased investor attention as market sentiment shifts following favorable financial results and sustained earnings growth. The stock is currently trending due to active discussions regarding its strong valuation compared to international streaming peers, persistent share buyback programs, and strategic focus on monetizing its user base through subscription services.

Atour Lifestyle Holdings Ltd. engages in the development of lifestyle brands around hotel. Its brands includes: Atour Hotel, Atour S, Atour Light, Atour X Hotel, ZHOTEL and A.T. House. The company was founded by Hai Jun Wang on April 10, 2012 and is headquartered in Shanghai, China.

Atour Lifestyle Holdings Ltd - ADR

Atour Lifestyle Holdings is surging on optimism surrounding China's easing of COVID-19 restrictions, fueling investor excitement around its hospitality network expansion and retail product growth. The community is buzzing with speculation about potential short-term volatility, with many traders closely monitoring volume spikes and technical breakout patterns as the stock gains traction as a momentum play.

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its products include Tandem Mobi System and t:slim X2 Insulin Pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.

Tandem Diabetes Care Inc

Tandem Diabetes is currently trending as investors react to a significant revenue beat and reaffirmed full-year sales guidance, with community sentiment shifting between optimistic growth potential and concerns over competitive pressure. Many traders are actively monitoring the stock's recent volatility and potential as a long-term acquisition target, while others debate the impact of new technology launches on its market share.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

The XRP community is currently polarized as the Bitwise XRP ETF launch drives intense debate over its role in institutional adoption versus speculative price manipulation. Traders remain divided between those aggressively buying into the current price volatility and others expressing deep skepticism about the asset's long-term utility and historical price action.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is seeing high volatility following the GTC keynote, where CEO Jensen Huang revealed a $1 trillion revenue outlook for its Blackwell and Vera Rubin platforms through 2027. Despite the massive long-term demand visibility and new partnerships with Uber and global automakers, the stock is experiencing significant intraday price swings as retail call buyers and institutional market makers navigate the high volume of options activity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Candel Therapeutics Inc. stock ended Wednesday deep in the red but rose 1.3% in extended trading after the company announced encouraging data from a cancer drug trial.The company reported final survival data from a Phase 2a trial of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-jumps-on-canaccord-buy-rating/ch5uUlPRwp">CAN-2409</a> in advanced lung cancer patients who did not respond well to immune checkpoint inhibitors (ICI).&nbsp;The median overall survival (mOS) was 24.5 months for those receiving two courses of CAN-2409, significantly higher than the 9.8-11.8 months seen in similar patients receiving standard chemotherapy.The study included 46 fully treated patients, with 37% of those with progressive disease still alive after two years.&nbsp;Patients with non-squamous non-small cell lung cancer (NSCLC) showed the most potent response, with a mOS of 25.4 months in this group. Biomarker analysis indicated a stronger immune response in these patients than in those with squamous NSCLC.The treatment also appeared to induce a systemic immune response, as 69% of patients with multiple tumors saw reductions in untreated lesions.&nbsp;CAN-2409 maintained a favorable safety profile throughout the extended follow-up period, the company added.The news sent message volume about Candel on Stocktwits soaring by over 120%, with sentiment climbing further within the ‘neutral’ territory (53/100) from a day ago.<figure class="image"><img style="aspect-ratio:1318/302;" src="https://news.stocktwits-cdn.com/CADL_sentiment_and_message_volume_as_of_Macrh_26_png_1c49d17460.webp" alt="CADL sentiment and message volume as of Macrh 26.png" width="1318" height="302"><figcaption>CADL sentiment and message volume as of Macrh 26. | source: Stocktwits</figcaption></figure>One optimistic user said CAN-2409 "is worth billions," adding that Candel also had successful phase-3 trials in prostate cancer and a successful phase-2 in pancreatic cancer.<stembedurl>https://stocktwits.com/strategicmind/message/609387743</stembedurl>Another compared Candel to small-cap biotech firms that were acquired by established pharma giants such as Gilead and Pfizer for tens of billions of dollars, saying the company “will join this GOAT rodeo in no time.”<stembedurl>https://stocktwits.com/chrundel/message/609386559</stembedurl>“I could see this becoming [the] standard of care for adenocarcinoma of the lung,” said another user based on the data.<stembedurl>https://stocktwits.com/Uromaster/message/609354605</stembedurl>Last month, Candel shared updated survival data from Phase 2a trials of CAN-2409 in pancreatic cancer.&nbsp;Meanwhile, Phase 1b survival data for CAN-3110 in recurrent high-grade glioma is expected in the fourth quarter of 2025, and the company plans to submit a Biologics License Application (BLA) for CAN-2409 in prostate cancer in Q4 2026.Candel stock is down about 12% this year but has gained more than 390% in the past 12 months.&nbsp;According to Koyfin, three out of four analysts covering Candel rate it ‘buy’ while one recommends a ‘strong buy.’For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration showing chimeric antigen receptor (CAR) T cells (blue and green) being used to treat non-small cell lung cancer (NSCLC). | Representative image: Getty Images

Candel’s Final Survival Data From Lung Cancer Drug Trial Lifts Stock After-Hours, Fuels Retail Optimism

The study included 46 fully treated patients, with 37% of those with progressive disease still alive after two years. 

Equity

The study included 46 fully treated patients, with 37% of those with progressive disease still alive after two years. 


Shares of Candel Therapeutics Inc. surged nearly 10% on Wednesday and extended gains in after-hours trading following a bullish call from Wall Street.Canaccord initiated coverage on the stock with a ‘Buy’ rating and a $20 price target, implying a 91% upside from the last close.&nbsp;The research firm expects continued clinical success for Candel’s lead asset, CAN-2409, in prostate, pancreatic, and non-small cell lung cancer.&nbsp;In testing so far, CAN-2409 has shown a significant increase in median overall survival. If this trend continues, it could become a “best-in-class therapy” for borderline resectable pancreatic ductal adenocarcinoma, according to the analyst.&nbsp;On Stocktwits, sentiment turned ‘extremely bullish’ on Wednesday as message volume jumped by 50% and new followers increased by 4%.&nbsp;<figure class="image"><img style="aspect-ratio:1316/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/CADL_sentiment_and_message_volume_Feb_19_d3c9416772.png" alt="CADL sentiment and message volume Feb 19.png" width="1316" height="316"><figcaption>CADL sentiment and message volume Feb 19 | source: Stocktwits</figcaption></figure>Traders speculated that upcoming data could drive a major rally, with some predicting that strong results from the pancreatic study could push shares into the $30-$40 range.<stembedurl>https://stocktwits.com/Xanderzzzzzzz/message/604910450</stembedurl><stembedurl>https://stocktwits.com/drizz/message/604899234</stembedurl>Last week, BofA Securities also&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-surges-on-bofa-buy-call/chPzAKRRtG">initiated</a> coverage on Candel with a ‘Buy’ rating and a $15 price target, citing promising early data for CAN-2409 and CAN-3110 as key drivers of its bullish outlook.&nbsp;The research firm noted that CAN-2409’s early results in prostate cancer suggest a potential breakthrough, while CAN-3110 has shown signs of nearly doubling overall survival in patients with recurrent high-grade glioma.Candel has outlined several key milestones ahead.&nbsp;Updated overall survival data from Phase 2a trials of CAN-2409 in pancreatic and non-small cell lung cancer is expected in the first quarter of 2025.&nbsp;Phase 1b survival data for CAN-3110 in recurrent high-grade glioma is set for the fourth quarter of 2025, while a Biologics License Application (BLA) submission for CAN-2409 in prostate cancer is targeted for the fourth quarter of 2026.<a href="https://stocktwits.com/symbol/CADL">Candel stock</a> is up more than 22% this year. Short interest was 6.2% as of last week, down from 14.1% at the start of the year, per Koyfin data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Candel Therapeutics Stock Rallies On Canaccord’s Vote Of Confidence In Lead Cancer Drug: Retail Traders Rejoice

CAN-2409 could become a “best-in-class therapy” for borderline resectable pancreatic ductal adenocarcinoma, according to the analyst. 

Shares of Mullen Automotive Inc. (MULN) plunged nearly 28% on Wednesday, hitting new record lows after quarterly results showed widening losses that further dented retail investor confidence.The struggling EV maker reported first-quarter (Q1) revenue of $2.9 million, stating that it produced more revenue this quarter than in the past two fiscal years combined.&nbsp;However, net losses ballooned by over 46%, with a net loss of $114.9 million attributable to common shareholders after preferred dividends.While adjusted losses per share narrowed to $661.33 from $91,940.42 a year earlier, the company noted that this figure accounted for retroactive reverse stock splits, including a 1:60 split that took <a href="https://stocktwits.com/news-articles/markets/equity/muln-stock-slides-on-reverse-split-plan/ch5icstRHs">effect</a> this week.&nbsp;Most losses were non-cash expenses totaling $91 million, making up 79% of the quarter's total loss.CEO David Michery tried to highlight a positive milestone, saying that $4.4 million worth of invoices were issued and $6 million in vehicle payments were received, marking Mullen's strongest quarter to date.&nbsp;The company's Bollinger segment completed the sale of 20 units, generating $2.8 million in revenue.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/CVNA_sentiment_and_message_volume_Feb_19_d795e38b8c.png" alt="CVNA sentiment and message volume Feb 19.png" width="1318" height="324"><figcaption>CVNA sentiment and message volume Feb 19 | source: Stocktwits</figcaption></figure>On Stocktwits, sentiment turned 'extremely bearish,' with message volume ticking up as traders weighed Mullen's financial strain.One user pointed to Mullen's crippling balance sheet, noting that the company already owed a lot of money to GEM Group from a lost arbitration case."This is an insolvent company," the user concluded.<stembedurl>https://stocktwits.com/KendallP/message/604814133</stembedurl>Another skeptical trader mocked potential buyers.<stembedurl>https://stocktwits.com/FourFingerFred/message/604807224</stembedurl>Mullen in December submitted a modified plan to the U.S. Department of Energy (DOE) seeking $55 million in matching funds to support U.S.-based battery and pack production.&nbsp;Additionally, the company has implemented cost-cutting measures, reducing headcount and personnel costs by $13 million annually.However, <a href="https://stocktwits.com/symbol/MULN">MULN stock</a> has lost over 99% of its value in the past year, reflecting a sharp decline in investor confidence amid legal hurdles, financial distress, and lackluster sales growth.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Bear Market and falling chart - stock photo

Mullen's Stock Plumbs New Depths After Q1 Net Loss Balloons By 46%, Retail Traders Throw In The Towel

Most losses were non-cash expenses totaling $91 million, making up 79% of the quarter's total loss.

Mullen Automotive shares slid on Friday morning after plunging over 26% in the previous session, as&nbsp;investors responded negatively to the EV maker’s 1-for-60 reverse stock split&nbsp;announcement.&nbsp;The move aims to help Mullen regain compliance with Nasdaq’s $1 minimum bid price rule. The split will take effect on Feb. 18.On Stocktwits, Mullen’s sentiment meter shifted to ‘neutral’ from ‘bullish’ amid increased message volume.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/MULN_sentiment_Feb_14_4cf83233f7.png" alt="MULN sentiment Feb 14.png" width="1318" height="324"><figcaption>MULN sentiment and message volume on Feb 14 as of 10:00 am ET | source: Stocktwits</figcaption></figure>Bearish posts pointed to reports of a legal setback: Mullen lost a lawsuit against GEM Group, which it had accused of unregistered securities dealing and market manipulation.&nbsp;<stembedurl>https://stocktwits.com/KendallP/message/604248065</stembedurl>A court&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://storage.courtlistener.com/recap/gov.uscourts.nysd.615724/gov.uscourts.nysd.615724.148.0.pdf">filing</a> confirmed the ruling against Mullen, ordering the company to pay over $26 million in damages plus interest within 90 days — a sum that bearish retail traders noted far exceeds the EV maker’s current market capitalization and annual revenue.Mullen only recently moved from pre-revenue development to commercial EV sales, reporting $400,000 in revenue for fiscal 2023 and about $1.1 million in fiscal 2024.&nbsp;However, its net loss for the twelve months ended Sept. 30, 2024, widened as non-cash impairment charges climbed to $119.2 million from $84.6 million the prior year.&nbsp;The company&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/01/24/3015112/0/en/Mullen-Reports-Improved-2024-Financial-Results.html">cited</a> ongoing funding challenges and a sharp decline in its market cap as key drivers of the charge.Cash and equivalents dropped to $10.3 million from $155.3 million a year earlier, while total debt stood just below $20 million.Still, some bullish traders speculated that Mullen’s upcoming quarterly earnings report could trigger a rebound, suggesting the reverse split was strategically timed ahead of the release.&nbsp;<stembedurl>https://stocktwits.com/DEDBEARS/message/604286050</stembedurl>The company has also seen some recent positive developments, including last month’s purchase of battery line equipment from Nikola for its Fullerton facility and new orders for its electric cargo vans from universities in Los Angeles and the San Francisco Bay Area.Earlier this year, Mullen reported better-than-expected road testing&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://electrek.co/2024/02/29/mullen-sees-better-than-expected-road-testing-results-from-energy-dense-solid-state-batteries/">results</a> for its solid-state batteries, showing promising gains in driving range.&nbsp;Founded in 2014, the company initially sought to revive a defunct EV model before pivoting to develop its vehicles.&nbsp;After a 2020 merger, Mullen <a href="https://stocktwits.com/news-articles/markets/equity/muln-stock-dips-after-cost-cut-plans/cJcQXH5REP">acquired</a> a majority stake in Bollinger Motors in 2023 and bought assets from bankrupt Electric Last Mile Solutions.Despite these efforts, investors remain cautious as Mullen navigates legal hurdles and financial strain.&nbsp;The stock has lost over 99% of its value in the past year, with the upcoming earnings report on Feb. 17 seen as a key test for the company’s growth narrative.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In 2022, Mullen spent $148 million acquiring Bollinger Motors and another $240 million on Electric Last Mile Solutions. Photo courtesy: Mullen

Mullen Automotive Stock In Reverse Gear On 1-For-60 Reverse Split Plan: Retail Sentiment Mixed

The stock has lost over 99% of its value in the past year, with the upcoming earnings report on Feb. 17 seen as a key test for the company’s growth narrative.

Shares of Candel Therapeutics Inc.&nbsp;(CADL)&nbsp;surged over 9% on Friday morning, reaching their highest level in nearly a month and setting the stage for their best weekly gain (+20%) since Dec. 20.BofA Securities initiated coverage of Candel with a 'Buy' rating and a $15 price target, according to The Fly, implying an upside of about 92% from the previous close.&nbsp;The brokerage highlighted promising early data for Candel's two lead drug candidates —&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/cadl-stock-soars-after-prostate-cancer-drug-trial-data/cJa3iD5R0a">CAN-2409</a> and CAN-3110 — as key drivers of its bullish outlook.The analyst noted that CAN-2409's early data in prostate cancer suggests the potential for a meaningful breakthrough, given the lack of significant advancements in available treatments.&nbsp;BofA added that CAN-3110 has shown early indications of nearly doubling overall survival in patients with recurrent high-grade glioma.Last month, Candel provided a broad update on what to expect this year and beyond:<ul style="list-style-type:circle;"><li>Q1 2025: Updated overall survival data from Phase 2a clinical trials of CAN-2409 in pancreatic ductal adenocarcinoma and non-small cell lung cancer.</li><li>Q4 2025: Phase 1b overall survival data for CAN-3110 in patients with recurrent high-grade glioma.</li><li>Q4 2026: Biologics License Application (BLA) submission for CAN-2409 in prostate cancer.</li><li>Upcoming scientific conferences: Presentation of Phase 3 data for CAN-2409 in prostate cancer.</li></ul>Candel also disclosed that its cash and cash equivalents stood at approximately $103 million as of&nbsp;Dec. 31, 2024, which the company expects to fund its operations into the first quarter of 2027.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/CADL_sentiment_and_message_volume_Feb_7_0ea124a0a6.png" alt="CADL sentiment and message volume Feb 7.png" width="1318" height="324"><figcaption>CADL sentiment and message volume Feb 7 as of 11 am ET | source: Stocktwits</figcaption></figure>Stocktwits sentiment on Candel flipped to ‘bullish’ (71/100) on Friday from a ‘bearish’ (42/100) reading last week, amid a spike in message volume.&nbsp;Retail traders cheered BofA's bullish rating, with one urging investors to stay long on the stock.<stembedurl>https://stocktwits.com/LongLTC/message/603284668</stembedurl>Adding to the optimism, a retail investor flagged a 13G&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/315066/000031506625000400/xslSCHEDULE_13G_X01/primary_doc.xml">filing</a> from Fidelity Investments on Friday, revealing that it now owns a 9.3% stake in Candel.<stembedurl>https://stocktwits.com/jzellner/message/603322436</stembedurl>Notably, according to Koyfin data, short interest in Candel stock dropped from 14.1% at the beginning of January to 6.9% by the end of the month.<a href="https://stocktwits.com/symbol/CADL">Candel shares</a> have skyrocketed 560% over the past 12 months — and with bullish sentiment building, some traders believe the rally is far from over.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Photo caption: BofA’s $15 price target implies an upside of about 92% from the previous close. | Image source: Getty Images

Candel Therapeutics Stock Headed For 20% Weekly Gains: Retail Over The Moon With BofA's 'Buy' Call

The analyst noted that CAN-2409's early data in prostate cancer suggests the potential for a meaningful breakthrough, given the lack of significant advancements in available treatments.

Current Price	$51.99
Prev Close	$51.73
Open	$52.04
Dividend Yield	N/A
50-Day Moving Average	$52.42
Beta	N/A
Avg. Volume	1,936.75
PE Ratio	N/A

52-Week High	$53.42
52-Week Low	$46.28
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

HDG
ProShares Hedge Replication ETF

Feed

News

Sentiment

Fundamentals

Info

Latest HDG News

HDGProShares Hedge Replication ETF